• 03/18/2026, Sophia Antipolis, France

    Median Technologies achieves ISO 13485:2016 certification for eyonis® Medical Device Quality Management System

    Press release – For immediate release – 5:45 pm CET Median Technologies achieves ISO 13485:2016 certification for eyonis® Medical Device Quality Management System Certification of a robust and compliant Quality Management System for AI-based Software as Medical Devices, as per internationally recognized medical device regulatory standards Pledge of quality to support the industrialization, scaling, and deployment […]
    Read more Download 20260318_PR_ISO15485_EN_final.pdf
  • 03/13/2026, Sophia Antipolis, France

    Median Technologies meets the eligibility conditions for the PEA-PME scheme

    Press release – For immediate release – 5:45 pm CET Median Technologies meets the eligibility conditions for the PEA-PME scheme Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading […]
    Read more Download 20260313_PR_PEAPME_EN.pdf
  • 03/09/2026, Sophia Antipôlis, France

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2026

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20260309_PR_shares_votingrights_Feb2026.pdf
  • 03/02/2026, Sophia Antipolis, France

    Median Technologies to showcase eyonis® LCS, its AI/ML-based Software as a Medical Device for lung cancer screening, at the European Congress of Radiology

    The Median eyonis® team will welcome attendees at Booth #AI-16, AI Exhibition, Expo X1, from March 4 to March 7, to present the latest developments related to eyonis® Lung Cancer Screening (LCS), its AI-powered Software as a Medical Device (SaMD).
    Read more Download 20260302_PR_ECR2026_EN_final.pdf
  • 02/27/2026, Sophia Antipolis, France

    Median Technologies to present at the TD Cowen 46th Annual Health Care Conference

    Fredrik Brag, Median’s CEO and Founder, will present on the Company latest developments and upcoming milestones on Wednesday, March 4 at 11:10 am ET (6:10 pm CET).
    Read more Download 20260227_PR_TDcowen2026_EN-1.pdf
  • 02/23/2026, Sophia Antipolis, France

    Median to Host Webcasts Highlighting Strategic Advances Driving U.S. Deployment of eyonis® LCS

    The webcasts, titled “Transforming Lung Cancer Screening: Strategic Updates on eyonis® LCS,” will present the Company’s recent strategic milestones supporting the U.S. deployment and commercialization of eyonis® LCS, Median’s AI-based CADe/CADx Software as a Medical Device for lung cancer screening.
    Read more Download 20260223_PR_Webcasteyonis_EN-2.pdf
  • 02/18/2026, Sophia Antipolis, France

    FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

    Median Technologies today announced the appointment of Oran Muduroglu as President of Median eyonis Inc.,  Median’s U.S. subsidiary.Oran Muduroglu will lead the U.S. launch and scale-up of eyonis® LCS, the Company’s AI-powered Software as a Medical Device (SaMD) for lung cancer screening, following U.S. Food and Drug Administration (FDA) 510(k) clearance announced on February 9, 2026.
    Read more Download 20260218_PR_MedianeyonisInc_final_EN.pdf
  • 02/12/2026, Sophia Antipolis, France and Chicago, IL, USA

    Median Technologies announces collaboration with Tempus to expand access to eyonis® LCS Software as a Medical Device in the United States

    The collaboration follows FDA 510(k) clearance for eyonis® LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus Pixel platform.
    Read more Download 20260212_PR_MT-Tempus_EN_final.pdf
  • 02/11/2026, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of January 31, 2026

    Disclosure of total number of voting rights and number of shares in the capital as of January 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20260211_PR_shares_votingrights_Jan2026.pdf
  • 02/09/2026, Sophia Antipolis, France

    Median Technologies receives FDA 510(k) clearance for eyonis® LCS, the first AI tech-based detection and diagnosis device for lung cancer screening

    eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unnecessary follow-up procedures, and has the potential to help save hundreds of thousands of lives in the US alone.
    Read more Download 20260209_PR_FDAclearance_EN_Final.pdf
    • 1 … 45